0.01
+0(+0.00%)
Currency In USD
Address
955 Chesterbrook Boulevard
Chesterbrook, PA 19087
United States of America
Phone
610 354 8840
Website
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
January 31, 2014
| Name | Title | Pay | Year Born |
| Carrie L. Bourdow | President, Chief Executive Officer & Chairman | 1.08M | 1963 |
| Robert T. Yoder | Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer | 490,639 | 1966 |
| Mark A. Demitrack | Senior VP & Chief Medical Officer | 741,345 | 1958 |
| Michael Catalano | Vice President of Marketing | 0 | N/A |
| Katrine Sutton | Principal Financial Officer & principal accounting officer | 0 | 1977 |
| Howard A. Rockman | Scientific Founder, Consultant and Member of Scientific Advisory Board | 0 | N/A |
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.